Clinical Research Directory

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Age ≥18 years. 4. Histologically confirmed advanced uveal melanoma. 5. HLA-A\*02:01 positive as determined per standard of care before enrollment in the study. 6. Planned treatment with tebentafusp as first-line systemic therapy for advanced uveal melanoma per standard of care. 7. For participants able to become pregnant: use of highly effective contraception for at least 4 weeks prior to initiation of tebentafusp and agreement to use such a method for duration of tebentafusp treatment until 6 months after the last dose of tebentafusp. 8. For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner from trial initiation and for duration of tebentafusp treatment until 6 months after the last dose of tebentafusp. Exclusion Criteria: 1. Use of systemic corticosteroid (including hydrocortisone) within 3 weeks of study entry. 2. Pregnancy or lactation. 3. Known severe hypersensitivity reaction to monoclonal antibodies or biologics.